BACKGROUND:Resistant hypertension (RH) is a growing health burden in this country affecting as many as 1 in 5 adults being treated for hypertension. Resistant hypertension is associated with increased risk of adverse cardiovascular disease (CVD) events and all-cause mortality. Strategies to reduce blood pressure (BP) in this high-risk population are a national priority. METHODS:TRIUMPH is a single-site, prospective, randomized clinical trial to evaluate the efficacy of a center-based lifestyle intervention consisting of exercise training, reduced sodium and calorie Dietary Approaches to Stop Hypertension eating plan, and weight management compared to standardized education and physician advice in treating patients with RH. Patients (n = 150) will be randomized in a 2:1 ratio to receive either a 4-month supervised lifestyle intervention delivered in the setting of a cardiac rehabilitation center or to a standardized behavioral counseling session to simulate real-world medical practice. The primary end point is clinic BP; secondary end points include ambulatory BP and an array of CVD biomarkers including left ventricular hypertrophy, arterial stiffness, baroreceptor reflex sensitivity, insulin resistance, lipids, sympathetic nervous system activity, and inflammatory markers. Lifestyle habits, BP, and CVD risk factors also will be measured at 1-year follow-up. CONCLUSIONS: The TRIUMPH randomized clinical trial (ClinicalTrials.gov NCT02342808) is designed to test the efficacy of an intensive, center-based lifestyle intervention compared to a standardized education and physician advice counseling session on BP and CVD biomarkers in patients with RH after 4 months of treatment and will determine whether lifestyle changes can be maintained for a year.
RCT Entities:
BACKGROUND: Resistant hypertension (RH) is a growing health burden in this country affecting as many as 1 in 5 adults being treated for hypertension. Resistant hypertension is associated with increased risk of adverse cardiovascular disease (CVD) events and all-cause mortality. Strategies to reduce blood pressure (BP) in this high-risk population are a national priority. METHODS: TRIUMPH is a single-site, prospective, randomized clinical trial to evaluate the efficacy of a center-based lifestyle intervention consisting of exercise training, reduced sodium and calorie Dietary Approaches to Stop Hypertension eating plan, and weight management compared to standardized education and physician advice in treating patients with RH. Patients (n = 150) will be randomized in a 2:1 ratio to receive either a 4-month supervised lifestyle intervention delivered in the setting of a cardiac rehabilitation center or to a standardized behavioral counseling session to simulate real-world medical practice. The primary end point is clinic BP; secondary end points include ambulatory BP and an array of CVD biomarkers including left ventricular hypertrophy, arterial stiffness, baroreceptor reflex sensitivity, insulin resistance, lipids, sympathetic nervous system activity, and inflammatory markers. Lifestyle habits, BP, and CVD risk factors also will be measured at 1-year follow-up. CONCLUSIONS: The TRIUMPH randomized clinical trial (ClinicalTrials.gov NCT02342808) is designed to test the efficacy of an intensive, center-based lifestyle intervention compared to a standardized education and physician advice counseling session on BP and CVD biomarkers in patients with RH after 4 months of treatment and will determine whether lifestyle changes can be maintained for a year.
Authors: Stacie L Daugherty; J David Powers; David J Magid; Heather M Tavel; Frederick A Masoudi; Karen L Margolis; Patrick J O'Connor; Joe V Selby; P Michael Ho Journal: Circulation Date: 2012-02-29 Impact factor: 29.690
Authors: Fernando Dimeo; Nikolaos Pagonas; Felix Seibert; Robert Arndt; Walter Zidek; Timm H Westhoff Journal: Hypertension Date: 2012-07-16 Impact factor: 10.190
Authors: Mark I Davis; Kristian B Filion; David Zhang; Mark J Eisenberg; Jonathan Afilalo; Ernesto L Schiffrin; Dominique Joyal Journal: J Am Coll Cardiol Date: 2013-05-01 Impact factor: 24.094
Authors: Dharam J Kumbhani; P Gabriel Steg; Christopher P Cannon; Kim A Eagle; Sidney C Smith; Kevin Crowley; Shinya Goto; E Magnus Ohman; George L Bakris; Todd S Perlstein; Scott Kinlay; Deepak L Bhatt Journal: Eur Heart J Date: 2012-11-09 Impact factor: 29.983
Authors: Ingrid J M Scheffers; Abraham A Kroon; Jürg Schmidli; Jens Jordan; Jan J M Tordoir; Markus G Mohaupt; Friedrich C Luft; Hermann Haller; Jan Menne; Stefan Engeli; Jiri Ceral; Siegfried Eckert; Andrejs Erglis; Krzysztof Narkiewicz; Thomas Philipp; Peter W de Leeuw Journal: J Am Coll Cardiol Date: 2010-10-05 Impact factor: 24.094
Authors: Dawn E Epstein; Andrew Sherwood; Patrick J Smith; Linda Craighead; Carla Caccia; Pao-Hwa Lin; Michael A Babyak; Julie J Johnson; Alan Hinderliter; James A Blumenthal Journal: J Acad Nutr Diet Date: 2012-09-19 Impact factor: 4.910
Authors: James E Sharman; Thomas H Marwick; Deborah Gilroy; Petr Otahal; Walter P Abhayaratna; Michael Stowasser Journal: Hypertension Date: 2013-09-23 Impact factor: 10.190
Authors: David E Kandzari; Deepak L Bhatt; Paul A Sobotka; William W O'Neill; Murray Esler; John M Flack; Barry T Katzen; Martin B Leon; Joseph M Massaro; Manuela Negoita; Suzanne Oparil; Krishna Rocha-Singh; Craig Straley; Raymond R Townsend; George Bakris Journal: Clin Cardiol Date: 2012-05-09 Impact factor: 2.882
Authors: James A Blumenthal; Michael A Babyak; Christopher O'Connor; Steven Keteyian; Joel Landzberg; Jonathan Howlett; William Kraus; Stephen Gottlieb; Gordon Blackburn; Ann Swank; David J Whellan Journal: JAMA Date: 2012-08-01 Impact factor: 56.272
Authors: Patrick J Smith; James A Blumenthal; Alan L Hinderliter; Stephanie M Mabe; Jeanne E Schwartz; Forgive Avorgbedor; Andrew Sherwood Journal: J Hypertens Date: 2019-05 Impact factor: 4.844
Authors: Branko Braam; Sandra J Taler; Mahboob Rahman; Jennifer A Fillaus; Barbara A Greco; John P Forman; Efrain Reisin; Debbie L Cohen; Mohammad G Saklayen; S Susan Hedayati Journal: Clin J Am Soc Nephrol Date: 2016-11-28 Impact factor: 8.237
Authors: Patrick J Smith; Andrew Sherwood; Alan L Hinderliter; Stephanie Mabe; Lana L Watkins; Linda Craighead; Krista Ingle; Crystal Tyson; Forgive Avorgbedor; Pao-Hwa Lin; William E Kraus; Lawrence Liao; James A Blumenthal Journal: J Hypertens Date: 2022-06-10 Impact factor: 4.776
Authors: Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White Journal: Hypertension Date: 2018-11 Impact factor: 10.190
Authors: James A Blumenthal; Alan L Hinderliter; Patrick J Smith; Stephanie Mabe; Lana L Watkins; Linda Craighead; Krista Ingle; Crystal Tyson; Pao-Hwa Lin; William E Kraus; Lawrence Liao; Andrew Sherwood Journal: Circulation Date: 2021-09-27 Impact factor: 39.918